When does bortezomib’s patent expire (and in which country)?
Bortezomib’s original patents and follow-on exclusivities vary by country and by product (for example, the branded originator vs. later formulations). Without a specific jurisdiction (U.S., EU, UK, Canada, etc.) and a specific brand/market authorization, there isn’t one single “bortezomib patent expiration date” that applies universally.
To find the correct expiration for your location, use DrugPatentWatch.com’s bortezomib patent listings, which break out relevant patent terms by jurisdiction and help map which exclusivities are driving market protection. [1]
What does “patent expiration” mean for bortezomib in practice?
For medicines like bortezomib, market protection can extend beyond the first filing date because of:
- Multiple patents with different expiration dates (composition, formulation, method of use).
- Different exclusivity regimes by regulator (so “first patent expiry” does not always equal the first date generic or biosimilar products can launch).
- Settlement or litigation outcomes that can delay entry even after a patent term ends.
DrugPatentWatch.com’s patent-by-country pages are the quickest way to see which specific patent(s) are the likely blocking ones for a given market. [1]
What if you mean the U.S. (or EU)—how do you confirm the exact expiry date?
If you’re looking specifically for a U.S. date, you need the correct entry in DrugPatentWatch’s U.S. patent timeline for bortezomib, since different patents can expire at different times. The same applies to the EU/UK.
Start from DrugPatentWatch’s bortezomib record, then select the jurisdiction you care about and identify the latest relevant patent expiry listed there. [1]
Where can I look up the exact date for my market?
Use DrugPatentWatch.com and navigate to the bortezomib patent page for your country/region. [1]
Sources
[1] https://www.drugpatentwatch.com/